Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: An Italian observational study

Clinical Drug Investigation

Volumn 30, Issue SUPPL. 1, 2010, Pages 21-26

  Magnelli, Fernanda ^a   Biondi, Lorita ^a   Calabria, Roberto ^a   Fiore, Angelo ^a   Peluso, Eugenio ^a   Vonella, Domenico ^a   Rota, Amerigo Giuseppe ^a  

^a UOC SerT Cosenza Provincial Health Agency   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTHRALGIA; ARTICLE; BONE PAIN; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DISTRESS SYNDROME; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; OBSERVATIONAL STUDY; OPIATE ADDICTION; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; TREATMENT DURATION; WITHDRAWAL SYNDROME; ADDICTION; DIAGNOSIS; DRUG COMBINATION; DRUG DEPENDENCE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OPIOID-RELATED DISORDERS; PREVENTION AND CONTROL; PSYCHOLOGY; SUBLINGUAL DRUG ADMINISTRATION; SUBSTANCE ABUSE; SUBSTANCE WITHDRAWAL SYNDROME; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, SUBLINGUAL; ADULT; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; DRUG COMBINATIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952383313     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536010-000000000-00000     Document Type: Article

References (24)

1. US Department of Health andHuman Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol TIP 40. 2004.
2. National Institute on Drug Abuse. Principles of drug addiction treatment: a research based guide. Evidence-based approaches to drug addiction treatment. [cited 2009 21 Oct]; Available from: http://www.drugabuse.gov/PODAT/Evidence. html#Pharm.
3. Goldman FR, Thistel CI. Diversion of methadone: illicit methadone use among applicants to twometropolitan drug abuse programs. Int J Addict 1978 Aug; 13 (6): 855-862.
4. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003 (2): CD002207.
5. Prescribing Information - Methadone (Italy). [cited 2009 14 Nov]; Available from: http://www.pharmamarketing.it/cont/020ser/050pro/default.asp? method=Mostra-Contenuto&id-cont=61641.
6. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.Arch InternMed 2007 Dec 10; 167 (22): 2469-2475.
7. Best SE, Oliveto AH, Kosten TR. Opioid addiction: recent advances in detoxification and maintenance therapy. CNS Drugs 1996; 6 (4): 301-314.
8. Chapleo CB, Walter DS. The buprenorphine-naloxone combination product. Res Clin Forums 1997; 19 (2): 55-58.
9. Law FD, Myles JS, Daglish MRC. The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatria 2004; 16: 246-274.
10. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 2003 May 21; 70 (2 Suppl.): S29-37.
11. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003 May 21; 70 (2 Suppl.): S59-77.
12. Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988 Oct; 247 (1): 47-53.
13. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 Apr 17; 88 (1): 75-78.
14. Bell J, Byron G, Gibson A, et al. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 2004 Sep; 23 (3): 311-317.
15. European Medicines Agency. Scientific discussion (Suboxone) [online]. [cited 2007 21 Oct]; Available from: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/suboxone/069706en6.pdf.
16. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20 (9): 697-712.
17. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000 Dec 22; 61 (1): 85-94.
18. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 Sep 4; 349 (10): 949-958.
19. Kamien JB, Branstetter SA, Amass LA. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl 2008; 10 (4): 5-18.
20. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007 May; 164 (5): 797-803.
21. Reckitt Benckiser Pharmaceuticals Inc. Suboxone (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets)/Subutex (buprenorphineHCl sublingual tablets): US prescribing information [online]. [cited 2009 16 November]; Available from: http://www.suboxone.com/patients/pi.
22. Healy R. Effectiveness of two opioid antagonists in treating opioid-induced constipation. Br J Nurs 2009 Sep 10-23; 18 (16): 998-1002.
23. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008 Nov 5; 300 (17): 2003-2011.
24. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005 Aug; 100 (8): 1090-1100.